多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性对照研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (9): 1038-1041.

多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性对照研究

张玉琦, 徐文炜, 程灶火, 吴越, 顾君, 汤莉, 季萍, 李桂林

南京医科大学附属无锡精神卫生中心,无锡 214151,江苏

收稿日期:2012-04-16 修回日期:2012-05-21 发布日期:2012-09-25
作者简介:张玉琦, 男,副教授,研究方向:临床精神病学。E-mail: g_yqzhang@sohu.com
基金资助:
国家自然科学基金课题(30670714); 江苏省自然科学基金(BK2006028)

Efficacy and safety study of the donepezil combined olanzapine flow in the treatment of behavioral and psychological symptoms of dementia

ZHANG Yu-qi, XU Wen-wei, CHENG Zao-huo, WU Yue, GU Jun, TANG Li, JI Ping, LI Gui-lin

Wuxi Mental Health Center, Nanjing Medical College, Wuxi 214151,Jiangsu,China

Received:2012-04-16 Revised:2012-05-21 Published:2012-09-25

摘要/Abstract

摘要： 目的探讨多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性。方法 103例伴精神行为症状的痴呆病人随机分为多奈哌齐合并奥氮平组与单用奥氮平组。治疗前和研究结束时进行简易智力状态检查(MMSE)评分,在治疗2、4、6、8周末以痴呆病理行为评定量表(BEHAVE-AD)减分率评定疗效:≥60%为显效,≥30%为有效,<30%为无效。以副反应量表(TESS)评定记录治疗中各项药物不良反应。结果多奈哌齐合并奥氮平组MMSE评分较治疗前提高2分以上,治疗结束后组内比较差异有统计学意义 (t=2.060,P<0.05)。治疗前后BEHAVE-AD量表评分两组组内比较,至第4周末时均明显下降,差异有显著统计学意义(P<0.01 或P<0.05)。多奈哌齐合并奥氮平组有效率为 88.46%,显效率为 67.31%;单用奥氮平组有效率 70.59%,显效率为 45.10%,两组比较有效率和显效率差异均有统计学意义(χ²=5.067,P<0.05; χ²=5.701, P<0.05)。两组均无不能耐受的不良药物反应。结论多奈哌齐合并奥氮平治疗老年痴呆精神行为症状安全有效且优于单用奥氮平。

关键词: 多奈哌齐, 奥氮平, 老年痴呆精神行为症状

Abstract: AIM: To investigate the efficacy and safety of donepezil combined olanzapine or single olanzapine in the treatment of behavioral and psychological symptoms. METHODS: 103 dementia patients with behavioral and psychological symptoms were randomly divided into donepezil combined olanzapine group and the single olanzapine group. The mini-mental state examination (MMSE) score were evaluated before treatment and the end of the study. The efficacies were evaluated in 2,4,6,8 weekend of the treatment by reduced rate of the behavioral pathology in Alzheimer's Disease Scale (BEHAVE-AD), ≥60% was markedly effective, ≥ 30% was effective, <30% was not effective. The treatment emergent symptom scale (TESS) assessment record treatment of the adverse drug reactions. RESULTS: The MMSE scores of donepezil combined olanzapine group increased more than two scores after the end than before treatment, it was statistically significant differences(t=2.060,P<0.05). The BEHAVE-AD scale scores of two groups before and after treatment compared to the fourth weekend were significantly decreased, there were statistically significant (P<0.01 or P<0.05). The effective rate was 88.46% and the markedly effective rate was 67.31% in donepezil combined olanzapine group.The effective rate was 70.59%, and the markedly effective rate was 45.10% in alone olanzapine group .There were statistically significant (χ²=5.067, P<0.05; χ²=5.701, P<0.05). There were no adverse drug reactions that can not tolerate. CONCLUSION: It is safe and effective that donepezil combined olanzapine treat behavioral and psychological symptoms of dementia patients, and better than single olanzapine.

Key words: Donepezil, Olanzapine, Behavioral and psychological symptoms of dementia

中图分类号:

R964

张玉琦, 徐文炜, 程灶火, 吴越, 顾君, 汤莉, 季萍, 李桂林. 多奈哌齐合并奥氮平治疗老年痴呆精神行为症状的疗效和安全性对照研究[J]. 中国临床药理学与治疗学, 2012, 17(9): 1038-1041.

ZHANG Yu-qi, XU Wen-wei, CHENG Zao-huo, WU Yue, GU Jun, TANG Li, JI Ping, LI Gui-lin. Efficacy and safety study of the donepezil combined olanzapine flow in the treatment of behavioral and psychological symptoms of dementia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1038-1041.

参考文献

[1] 盛树力. 老年性痴呆及相关疾病[M].北京:科学技术文献出版社,2006:67
[2] 于新主编. 老年精神医学新进展[M].1版.中华医学电子音像出版社,2011:98-112.
[3] Deberdt WG,Siegal A,Ahl J.Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia:a post-hoc analysis[J].Int J Gerlatr Psychiatry,2008,23(4):364-369.
[4] 彭丹涛,许贤豪,侯青云,等.安理申治疗轻中度阿尔茨海默病有效性及安全性的临床研究[J].中华神经科杂志,2002,35(1):19.
[5] 盛建华,陈美娟.阿尔茨海默病病理行为评分表信度和效度[J].临床精神医学杂志,2001,11:57-59.
[6] 喻东山,高振忠.精神科合理用药手册[M].南京:江苏科学技术出版社,2005:162-163.
[7] Starr JM,Lonie J.Relationship between behavioural and psychological symptoms of dementia and cognition in Alzheimer's disease[J].Dement Geriatr Cogn Disord,2007,24(5):343-347.
[8] Hollingworth P,Hamshere ML,Moskvina V.Four components describe behavioral symptoms in 1120 individuals with late-onset Alzheimer's disease[J].J Am Geriatr Soc,2006,54(9):1348-1354.
[9] Suh GH,Greenspan AJ,Choi SK.Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia[J].Int J Geriatr Psychiatry,2006,21(7):654-660.
[10] Stip E, Chouinard S, Boulay LJ.On the trail of a cognitive enhancer for the treatment of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29:219-232.
[11] Jia JP,Jia JM,Zhou WD,et a1.Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer,S disease and vascular dementia[J].Chin Med J,2004,117(8):1161.
[12] Wilkinson R,Doody R,Helme R,et a1.Donepezil in vascular dementia:a randomized placebo-controlled study[J].Neurology,2003,61(2):479.

[1]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[2]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[3]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[4]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[5]	曾慧, 屈刚, 肖兰, 田小娟, 易宏辉, 尹龙武, 孙红. 奥氮平对脂肪细胞UCP2和aP2表达的影响[J]. 中国临床药理学与治疗学, 2015, 20(2): 151-154.
[6]	倪平, 吕海龙, 国效峰, 张丽丽, 许林勇. 利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较[J]. 中国临床药理学与治疗学, 2014, 19(2): 182-185.
[7]	俞凌燕, 楼洪刚, 阮邹荣, 江波, 陈金亮. 基于偏最小二乘模型的奥氮平血药达峰浓度与个体内在因素的相关性研究[J]. 中国临床药理学与治疗学, 2012, 17(9): 1022-1025.
[8]	钟智勇, 张明, 王继辉, 吴小立. 利培酮口服液与奥氮平治疗脑器质性精神障碍疗效与安全性分析[J]. 中国临床药理学与治疗学, 2012, 17(9): 1047-1051.
[9]	杭荣华, 程万良, 王瑞权, 吴明飞. 奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较[J]. 中国临床药理学与治疗学, 2012, 17(7): 812-815.
[10]	许本健, 陈菊凤. 急性期精神分裂症转换帕利哌酮治疗的疗效及安全性[J]. 中国临床药理学与治疗学, 2012, 17(2): 215-219.
[11]	吴小立, 王继辉, 钟智勇, 韩自力. 阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 1016-1020.
[12]	温盛霖, 程敏锋, 王厚亮. 利培酮和奥氮平对精神分裂症患者血浆非酶类抗氧化物水平的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 1039-1041.
[13]	朱广球, 尤匡掌, 周纲. 盐酸多奈哌齐对老年人术后认知功能的影响[J]. 中国临床药理学与治疗学, 2011, 16(8): 903-907.
[14]	钟智勇, 吴小立, 程敏锋, 张晋碚. 舒必利与奥氮平治疗神经性厌食症患者的对照研究[J]. 中国临床药理学与治疗学, 2011, 16(4): 423-426.
[15]	袁国锋, 俞玉礼. 奥氮平治疗老年精神分裂症患者的疗效观察及对心电图的影响[J]. 中国临床药理学与治疗学, 2011, 16(3): 304-308.